Open AccessSteroid-sparing maintenance immunotherapy for MOG-IgG associated disorder
Author(s) -
John J. Chen,
Eoin P. Flanagan,
M. Tariq Bhatti,
Jiraporn Jitprapaikulsan,
Divyanshu Dubey,
Alfonso Sebastian S Lopez Chiriboga,
James P. Fryer,
Brian G. Weinshenker,
Andrew McKeon,
JanMendelt Tillema,
Vanda A. Len,
Claudia F. Lucchinetti,
Amy Kunchok,
Collin M. McClelland,
Michael S. Lee,
Jeffrey L. Bennett,
Victoria S. Pelak,
Gregory Van Stavern,
OreOfeoluwatomi O Adesina,
Eric Eggenberger,
Marie D Acierno,
Dean M. Wingerchuk,
Byron L. Lam,
Heather E. Moss,
Shan Beres,
Aubrey L. Gilbert,
Veeral S. Shah,
Grayson W. Armstrong,
Gena Heidary,
Dean M. Cestari,
Hadas StiebelKalish,
Sean J. Pittock
Publication year - 2020
Publication title -
neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.91
H-Index - 364
eISSN - 1526-632X
pISSN - 0028-3878
DOI - 10.1212/wnl.0000000000009758
Subject(s) - medicine , rituximab , multiple sclerosis , immunotherapy , retrospective cohort study , azathioprine , immunology , surgery , disease , antibody , immune system
Myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) associated disorder (MOGAD) often manifests with recurrent CNS demyelinating attacks. The optimal treatment for reducing relapses is unknown. To help determine the efficacy of long-term immunotherapy in preventing relapse in patients with MOGAD, we conducted a multicenter retrospective study to determine the rate of relapses on various treatments.